Gastroenteropancreatic Neuroendocrine Tumors Gep Nets Market

DelveInsight’s ‘Gastroenteropancreatic Neuroendocrine Tumors—Market Insights, Epidemiology, and Market Forecast—2032’ report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Gastroenteropancreatic Neuroendocrine Tumors in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

 

The Gastroenteropancreatic Neuroendocrine Tumors market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Gastroenteropancreatic Neuroendocrine Tumors market Size from 2019 to 2032, segmented by seven major markets. The report also covers the current Gastroenteropancreatic Neuroendocrine Tumors treatment practice/algorithm and unmet medical needs to curate the best opportunities and assess the underlying market potential.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019–2032

Gastroenteropancreatic Neuroendocrine Tumors: Disease Understanding and Treatment Algorithm

Gastroenteropancreatic Neuroendocrine Tumors Overview

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are tumors that arise from neuroendocrine cells in the gut. These cells release hormones that control various functions of the digestive system. The symptoms of GEP-NETs depend on where the tumor is growing in the gut and whether it produces excess hormones. It is often that by the time of diagnosis, the tumors have spread to other organs such as the liver. GEP-NETs are debilitating as they often produce excess hormones that may cause severe symptoms, and they are life-threatening if they spread to other organs in the body.

 

The World Health Organization (WHO) 2010 and 2017 classification system categorizes GEP-NETs into three grades based on histological differentiation and cell proliferation index, guiding treatment decisions. Tumor grade is determined by the highest number of either Ki-67 protein or mitotic count, and it offers an important prognostic value for GEP-NETs. The median survival rates have been determined for all NETs across all locations by tumor grade. For individuals with grade 1 tumors, median survival is more than 16 years; for grade 2, about 8 years; and for grade 3, about 10 months. In 2017, WHO updated the staging classifications for pancreatic NETs (pNETs) to recognize well-differentiated grade 3 tumors. This will allow for more precisely targeted treatment options for grade 3 tumors. Poorly differentiated grade 3 pNETs may continue to be treated with standard systemic chemotherapy, whereas well- and moderately differentiated grade 3 pNETs have been shown to benefit from targeted therapies (everolimus or sunitinib). Well-differentiated pNETs may even benefit from surgery.

 

Surgery, the only curative treatment for GEP-NETs, is generally considered a first-line treatment for localized NETs. However, despite advances in diagnostics, GEP-NETs are often not identified for up to 5–7 years after clinical symptoms appear, as the symptoms are not specific. Approximately 21% of well-differentiated NETs, 30% of moderately differentiated NETs, and 50% of poorly differentiated or undifferentiated NETs are diagnosed in the metastatic stage. Thus, many patients with GEP-NETs are not candidates for surgery and require systemic therapy after diagnosis. The frontline treatment for metastatic disease is somatostatin analogs, and currently, two agents are FDA approved: [octreotide acetate] Sandostatin and lanreotide [Somatuline Depot]. If patients progress on frontline treatment, there is, at present, a lack of evidence regarding the next-best agent to choose from. Traditionally, mTOR inhibitor—everolimus or sunitinib [Sutent] — was acknowledged second-line agent, but with the recent approval of PRRT [peptide receptor radionuclide therapy], the choice of second-line therapy is debatable.

 

In the refractory setting, patients are encouraged to participate in clinical trials. For third- and fourth-line settings, there are some data regarding capecitabine/temozolomide, as well, especially in pancreatic NETs, in which the combination chemotherapy is very active. All available therapies for GEP-NETs, whether monotherapy or combination, are currently leveraged to treat this complex, diverse population of patients, yet no treatment has maintained progression free survival (PFS) indefinitely.

 

Clinicians admit that many aspects of GEP-NETs are still unknown, and substantial efforts must be made to understand the disease better while advancing treatment options. There is a particular need for Phase II and III clinical trials to gain insight into treatment for grade 3 tumors, which have received less attention in the past because of grade 3 tumor rarity and poor pathology.

 

Gastroenteropancreatic Neuroendocrine Tumors Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the Gastroenteropancreatic Neuroendocrine Tumors market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

 

The DelveInsight Gastroenteropancreatic Neuroendocrine Tumors market report gives a thorough understanding of Gastroenteropancreatic Neuroendocrine Tumors by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides the treatment algorithms and treatment guidelines for Gastroenteropancreatic Neuroendocrine Tumors in the US, Europe, and Japan.

Gastroenteropancreatic Neuroendocrine Tumors Epidemiology

The Gastroenteropancreatic Neuroendocrine Tumors epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the incident patient pool, trends, and assumptions undertaken.

 

Key Findings

The disease epidemiology covered in the report provides historical and forecasted Gastroenteropancreatic Neuroendocrine Tumors epidemiology segmented as the Incidence cases of Gastroenteropancreatic Neuroendocrine Tumors,  Grade-specific cases of Gastroenteropancreatic Neuroendocrine Tumors, Site-specific cases of Gastroenteropancreatic Neuroendocrine Tumors, Stage-specific cases of Gastroenteropancreatic Neuroendocrine Tumors, and Symptoms-specific cases of Gastroenteropancreatic Neuroendocrine Tumors.. The report includes the incident scenario of Gastroenteropancreatic Neuroendocrine Tumors symptoms in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country-wise Gastroenteropancreatic Neuroendocrine Tumors Epidemiology

The epidemiology segment also provides the Gastroenteropancreatic Neuroendocrine Tumors epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

The incident population of Gastroenteropancreatic Neuroendocrine Tumors in the 7MM countries was estimated to be 23,115 cases in 2020.

Gastroenteropancreatic Neuroendocrine Tumors Drug Chapters

The drug chapter segment of the Gastroenteropancreatic Neuroendocrine Tumors report encloses the detailed analysis of Gastroenteropancreatic Neuroendocrine Tumors marketed drugs and late stage (Phase-III, Phase-II/III, Phase-II, and Phase-I/II) pipeline drugs. It also helps understand the Gastroenteropancreatic Neuroendocrine Tumors clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Products detail in the report…

 

Gastroenteropancreatic Neuroendocrine Tumors Emerging Drugs

The current pipeline for GEP-NETs is extensive and consists of many key assets, namely, 177Lu-edotreotide PRRT, CAM2029, Surufatinib, and Opdivo.

 

177Lu-edotreotide (ITM’s therapeutic radiopharmaceutical) is the candidate that consists of two components: the medical radioisotope no-carrier-added lutetium-177 (n.c.a. 177Lu) and the targeting molecule edotreotide, a synthetic form of the peptide hormone somatostatin that targets NET-specific receptors. Edotreotide binds to these receptors and places the medical radioisotope n.c.a. lutetium-177 directly onto the diseased neuroendocrine cells to accumulate at the tumor site. N.c.a. lutetium-177 is internalized into the tumor cells and decays, releasing medical radiation (ionizing beta-radiation) with a maximum radius of 1.7 mm and destroying the tumor. The highly precise localization can result in the healthy tissue surrounding the targeted tumor being minimally affected.

 

CAM2029 (Camurus AB) is a ready-to-use, long-acting, subcutaneous depot of octreotide under development to treat three rare diseases; acromegaly, GEP-NET, and polycystic liver disease (PLD). CAM2029 has been successfully evaluated in four completed clinical Phase I and II studies and has shown promising results in Phase II multicenter study in patients with acromegaly and NET with well-maintained or improved biochemical control in patients with acromegaly and symptom control in patients with functional NET after switching from Sandostatin LAR.

Products detail in the report…

Gastroenteropancreatic Neuroendocrine Tumors Market Outlook

The Gastroenteropancreatic Neuroendocrine Tumors market outlook of the report builds a detailed comprehension of the historical, current, and forecasted Gastroenteropancreatic Neuroendocrine Tumors market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.

 

This segment gives a thorough detail of Gastroenteropancreatic Neuroendocrine Tumors market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, the Gastroenteropancreatic Neuroendocrine Tumors market in the 7MM is expected to change in the study period 2019–2032.

 

Surgery is the primary treatment option; curative surgery should be considered even in the case of metastatic disease, when possible. For more progressed diseases, debulking and palliative surgery may reduce symptom load as well as facilitate and improve the outcomes from subsequent treatments. If present, hormonal symptoms can usually be ameliorated with somatostatin analogs (SSA); a second-line option is interferon-alpha (IFN-alpha). Other treatments for GEP-NET include molecular targeted therapy, chemotherapy, and peptide receptor radionuclide therapy (PRRT). For liver metastases, surgical resection, hepatic artery embolization (HAE), selective internal radiation therapy (SIRT), and radiofrequency ablation (RFA) or microwave ablation (MWA) can be performed.

 

Key Findings

This section includes a glimpse of the Gastroenteropancreatic Neuroendocrine Tumors market in the 7MM. The market size of Gastroenteropancreatic Neuroendocrine Tumors in the seven major markets was USD 2,821.2 million in 2020.

 

The United States: Market Outlook

This section provides the total Gastroenteropancreatic Neuroendocrine Tumors market size and market size by therapies of Gastroenteropancreatic Neuroendocrine Tumors in the United States.

 

The United States accounts for the highest market size of Gastroenteropancreatic Neuroendocrine Tumors compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

 

Somatostatin Analogues (SSAs) – specifically, octreotide (Sandostatin) and lanreotide (Somatuline Depot) – are acknowledged as category 2A recommendations in 2019 from the National Comprehensive Cancer Network (NCCN) for managing GEP-NETs.

 

Sandostatin SC (octreotide acetate for injection) and Sandostatin LAR (octreotide acetate for injectable suspension) were the first somatostatin analogs approved in the US, the EU, and other countries to treat patients with certain symptoms associated with carcinoid tumors and other types of functional gastrointestinal and pancreatic neuroendocrine tumors.

 

Lanreotide, approved for adults by the FDA in 2007, is an SSA to slow the growth of GEP-NETs that has spread or cannot be removed by surgery. It is also indicated to treat carcinoid syndrome to reduce the need to use short-acting SSAs. Advanced somatostatin analogs, like lanreotide, have a newer, improved injectable design and are sturdier. This agent is administered subcutaneously. This is an agent that is given subcutaneously. In Europe, lanreotide can also be self-administered by the patient or healthcare giver at home, which is unfortunately not allowed in the United States. Ongoing studies are looking at the combination of various analogs with various systemic treatments.

To be continued in report

 

EU-5 Countries: Market Outlook

The total Gastroenteropancreatic Neuroendocrine Tumors market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are also mentioned.

 

Japan Market Outlook

The total Gastroenteropancreatic Neuroendocrine Tumors market size and market size by therapies of Gastroenteropancreatic Neuroendocrine Tumors in Japan are also mentioned.

Gastroenteropancreatic Neuroendocrine Tumors Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2019–2032. The analysis covers Gastroenteropancreatic Neuroendocrine Tumors market uptake by drugs, patient uptake by therapies, and sales of each drug. 

 

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Gastroenteropancreatic Neuroendocrine Tumors Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II/III, Phase II, and Phase I/II stage. It also analyses Gastroenteropancreatic Neuroendocrine Tumors’ key players involved in developing targeted therapeutics.

 

Major players include ITM Isotopen Technologien Muenchen, Camurus AB, Hutchison Medipharma Limited, and others whose key products are expected to get launched in the US market by 2032.

 

Pipeline Development Activities

The report covers collaborations, acquisition, merger, licensing, and patent details for Gastroenteropancreatic Neuroendocrine Tumors emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SMEs’ opinions working in the Gastroenteropancreatic Neuroendocrine Tumors domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or Gastroenteropancreatic Neuroendocrine Tumors market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the Gastroenteropancreatic Neuroendocrine Tumors market using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Gastroenteropancreatic Neuroendocrine Tumors, explaining their causes, signs and symptoms, pathophysiology, and currently available therapies.
  • Comprehensive insight has been provided into the Gastroenteropancreatic Neuroendocrine Tumors epidemiology and treatment in the 7MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Gastroenteropancreatic Neuroendocrine Tumors is provided, along with the assessment of new therapies, which will impact the current treatment landscape.
  • A detailed review of the Gastroenteropancreatic Neuroendocrine Tumors market, historical and forecasted, is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Gastroenteropancreatic Neuroendocrine Tumors market.

Report Highlights

  • In the coming years, the Gastroenteropancreatic Neuroendocrine Tumors market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world, which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Gastroenteropancreatic Neuroendocrine Tumors R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Gastroenteropancreatic Neuroendocrine Tumors. The launch of emerging therapies will significantly impact the Gastroenteropancreatic Neuroendocrine Tumors market.
  • A better understanding of disease pathogenesis will also contribute to developing novel therapeutics for Gastroenteropancreatic Neuroendocrine Tumors.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competitor, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Gastroenteropancreatic Neuroendocrine Tumors Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Gastroenteropancreatic Neuroendocrine Tumors Pipeline Analysis
  • Gastroenteropancreatic Neuroendocrine Tumors Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Gastroenteropancreatic Neuroendocrine Tumors Report Key Strengths

  • 11-years Forecast
  • 7MM Coverage
  • Gastroenteropancreatic Neuroendocrine Tumors Epidemiology Segmentation
  • Key Competitors
  • Highly Analyzed Market
  • Drugs Uptake

Gastroenteropancreatic Neuroendocrine Tumors Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness

Key Questions

Market Insights:

  • What was the Gastroenteropancreatic Neuroendocrine Tumors Market share (%) distribution in 2019, and how would it look in 2032?
  • What would be the Gastroenteropancreatic Neuroendocrine Tumors total market size and market size by therapies across the 7MM during the forecast period (2019–2032)?
  • What are the key findings pertaining to the market across 7MM, and which country will have the largest Gastroenteropancreatic Neuroendocrine Tumors market Size during the forecast period (2019–2032)?
  • At what CAGR is the Gastroenteropancreatic Neuroendocrine Tumors market expected to grow in the 7MM forecast period (2019–2032)?
  • What would be the Gastroenteropancreatic Neuroendocrine Tumors market outlook across the 7MM during the forecast period (2019–2032)?
  • What would be the Gastroenteropancreatic Neuroendocrine Tumors market growth till 2032, and what will be the resultant market Size in the year 2032?

 

Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of Gastroenteropancreatic Neuroendocrine Tumors?
  • What is the historical Gastroenteropancreatic Neuroendocrine Tumors patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Gastroenteropancreatic Neuroendocrine Tumors in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population pertaining to Gastroenteropancreatic Neuroendocrine Tumors?
  • Out of all 7MM countries, which country would have the highest prevalence of Gastroenteropancreatic Neuroendocrine Tumors during the forecast period (2018–2030)?
  • At what CAGR is the population expected to grow in the 7MM forecast period (2019–2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Gastroenteropancreatic Neuroendocrine Tumors?
  • What are the current treatment guidelines for treating Gastroenteropancreatic Neuroendocrine Tumors in the USA, Europe, and Japan?
  • What are the Gastroenteropancreatic Neuroendocrine Tumors marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies for the treatment of Gastroenteropancreatic Neuroendocrine Tumors?
  • How many therapies are developed by each company to treat Gastroenteropancreatic Neuroendocrine Tumors?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Gastroenteropancreatic Neuroendocrine Tumors?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Gastroenteropancreatic Neuroendocrine Tumors therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Gastroenteropancreatic Neuroendocrine Tumors and their status?
  • What have key designations been granted for the emerging therapies for Gastroenteropancreatic Neuroendocrine Tumors?
  • What are the global historical and forecasted markets for Gastroenteropancreatic Neuroendocrine Tumors?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Gastroenteropancreatic Neuroendocrine Tumors market
  • Organize sales and marketing efforts by identifying the best opportunities for Gastroenteropancreatic Neuroendocrine Tumors in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Gastroenteropancreatic Neuroendocrine Tumors market.
  • To understand the future market competition in the Gastroenteropancreatic Neuroendocrine Tumors market.

1. Key Insights

2. Report Introduction

3. Gastroenteropancreatic Neuroendocrine Tumors Market Overview at a Glance

3.1. Market Share (%) Distribution of Gastroenteropancreatic Neuroendocrine Tumors in 2019

3.2. Market Share (%) Distribution of Gastroenteropancreatic Neuroendocrine Tumors in 2032

4. Executive Summary of Gastroenteropancreatic Neuroendocrine Tumors

5. Disease Background and Overview

5.1. Introduction

5.2. Classification

5.3. Causes

5.4. Signs and Symptoms

5.5. Risk Factors

5.6. Genetics

5.7. Pathophysiology

5.8. Diagnosis

5.9. Treatment

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM Total Incidence of Gastroenteropancreatic Neuroendocrine Tumors

6.3. Epidemiology of Gastroenteropancreatic Neuroendocrine Tumors

6.4. The United States

6.4.1. Incidence of Gastroenteropancreatic Neuroendocrine Tumors in the United States

6.4.2. Grade-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in the United States

6.4.3. Tumor site-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in the United States

6.4.4. Stage-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in the United States

6.4.5. Symptom-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in the United States

6.5. EU5

6.5.1. Total Incidence of Gastroenteropancreatic Neuroendocrine Tumors in EU5

6.5.2. Germany

6.5.2.1. Grade-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Germany

6.5.2.2. Tumor site-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Germany

6.5.2.3. Stage-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Germany

6.5.2.4. Symptom-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Germany

6.5.3. France

6.5.3.1. Grade-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in France

6.5.3.2. Tumor site-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in France

6.5.3.3. Stage-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in France

6.5.3.4. Symptom-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in France

6.5.4. Italy

6.5.4.1. Grade-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Italy

6.5.4.2. Tumor site-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Italy

6.5.4.3. Stage-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Italy

6.5.4.4. Symptom-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Italy

6.5.5. Spain

6.5.5.1. Grade-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Spain

6.5.5.2. Tumor site-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Spain

6.5.5.3. Stage-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Spain

6.5.5.4. Symptom-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Spain

6.5.6. The United Kingdom

6.5.6.1. Grade-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in the UK

6.5.6.2. Tumor site-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in the UK

6.5.6.3. Stage-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in the UK

6.5.6.4. Symptom-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in the UK

6.6. Japan

6.6.1. Incidence of Gastroenteropancreatic Neuroendocrine Tumors in Japan

6.6.2. Grade-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Japan

6.6.3. Tumor site-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Japan

6.6.4. Stage-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Japan

6.6.5. Symptom-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Japan

7. Patient Journey

8. Marketed Drugs

8.1. Keycross Competition

8.2. Lutathera (lutetium Lu 177 dotatate): Advanced Accelerator Applications S.A. (Novartis)

8.2.1. Product Description

8.2.2. Regulatory Milestones

8.2.3. Other Development Activity

8.2.4. Safety and Efficacy

8.2.5. Side Effects

8.2.6. Product Profile

8.3. Somatuline Depot (Lanreotide): Ipsen Biopharmaceuticals

8.3.1. Product Description

8.3.2. Regulatory Milestones

8.3.3. Other Development Activity

8.3.4. Safety and Efficacy

8.3.5. Product Profile

8.4. Afinitor (everolimus): Novartis

8.4.1. Product Description

8.4.2. Regulatory Milestones

8.4.3. Safety and Efficacy

8.4.4. Side Effects

8.4.5. Product Profile

8.5. Sutent (Sunitinib Malate): Pfizer

8.5.1. Product Description

8.5.2. Regulatory Milestones

8.5.3. Safety and Efficacy

8.5.4. Side Effects

8.5.5. Product Profile

9. Emerging Drugs

9.1. Key Cross of Emerging Drugs

9.2. 177Lu-edotreotide PRRT: ITM Isotopen Technologien Muenchen

9.2.1. Product Description

9.2.2. Other Development Activities

9.2.3. Clinical Development

9.2.4. Clinical trials information

9.2.5. Safety and Efficacy

9.2.6. Product Profile

9.3. CAM2029 (Octreotide subcutaneous depot): Camurus AB

9.3.1. Drug Description

9.3.2. Other Development Activities

9.3.3. Clinical Development

9.3.4. Clinical Trials Information

9.3.5. Safety and Efficacy

9.3.6. Product Profile

9.4. Surufatinib: Hutchison Medipharma Limited

9.4.1. Drug Description

9.4.2. Other Development Activities

9.4.3. Clinical Development

9.4.4. Clinical Trials Information

9.4.5. Safety and Efficacy

9.4.6. Product Profile

9.5. Opdivo (Nivolumab): Bristol-Myers Squibb

9.5.1. Drug Description

9.5.2. Other Development Activities

9.5.3. Clinical Development

9.5.4. Clinical Trials Information

9.5.5. Safety and Efficacy

9.5.6. Product Profile

9.6. Lenvatinib (Lenvima): Eisai Limited|Experior S.L.

9.6.1. Drug Description

9.6.2. Other Development Activities

9.6.3. Clinical Development

9.6.4. Clinical Trials Information

9.6.5. Safety and Efficacy

9.6.6. Product Profile

9.7. PEN-221: Tarveda Therapeutics

9.7.1. Drug Description

9.7.2. Clinical Development

9.7.3. Clinical Trials Information

9.7.4. Safety and Efficacy

9.7.5. Product Profile

9.8. Cabozantinib: Ipsen|Roche Pharma AG|Exelixis|Bristol-Myers Squibb

9.8.1. Drug Description

9.8.2. Other Development Activities

9.8.3. Clinical Development

9.8.4. Clinical Trials Information

9.8.5. Safety and Efficacy

9.8.6. Product Profile

10. Analyst Views

11. Other Assets

11.1. Keycross

11.2. Keytruda (Pembrolizumab): Merck Sharp & Dohme Corp.

11.2.1. Drug Description

11.2.2. Clinical Development

11.2.3. Clinical Trials Information

11.2.4. Safety and Efficacy

11.2.5. Product Profile

11.3. Entrectinib (RXDX-101): Hoffmann-La Roche

11.3.1. Drug Description

11.3.2. Other Development Activities

11.3.3. Clinical Development

11.3.4. Clinical Trials Information

11.3.5. Safety and Efficacy

11.3.6. Adverse Effects

11.3.7. Product Profile

11.4. SOM 230 [Pasireotide Long-acting Release (LAR)]: Recordati Inc|Novartis Pharmaceuticals

11.4.1. Drug Description

11.4.2. Other Development Activities

11.4.3. Clinical Development

11.4.4. Clinical Trials Information

11.4.5. Safety and Efficacy

11.4.6. Product Profile

11.5. Abemaciclib: Eli Lilly and Company

11.5.1. Drug Description

11.5.2. Clinical Development

11.5.3. Clinical Trials Information

11.5.4. Product Profile

11.6. Belzutifan: Merck Sharp & Dohme Corp.

11.6.1. Drug Description

11.6.2. Other Development Activities

11.6.3. Clinical Development

11.6.4. Clinical Trials Information

11.6.5. Product Profile

11.7. Atezolizumab+Tivozanib: Genentech, Inc.|Aveo Oncology Pharmaceuticals

11.7.1. Drug Description

11.7.2. Other Development Activities

11.7.3. Clinical Development

11.7.4. Clinical Trials Information

11.7.5. Product Profile

11.8. Alectinib (Alecensa): Hoffmann-La Roche

11.8.1. Drug Description

11.8.2. Other Development Activities

11.8.3. Clinical Development

11.8.4. Clinical Trials Information

11.8.5. Safety and Efficacy

11.8.6. Product Profile

11.9. AlphaMedix (ORM2110/212Pb-DOTAMTATE): Radiomedix|Orano Med

11.9.1. Product Description

11.9.2. Other Development Activities

11.9.3. Clinical Development

11.9.4. Clinical trials information

11.9.5. Safety and Efficacy

11.9.6. Product Profile

11.10. Ramucirumab (Cyramza): Eli Lilly and Company

11.10.1. Product Description

11.10.2. Clinical Development

11.10.3. Clinical trials information

11.10.4. Product Profile

11.11. Lurbinectedin (PM01183): PharmaMar

11.11.1. Product Description

11.11.2. Clinical Development

11.11.3. Clinical trials information

11.11.4. Product Profile

11.12. Regorafenib (Stivarga): Bayer|Merck KGaA

11.12.1. Product Description

11.12.2. Clinical Development

11.12.3. Clinical trials information

11.12.4. Product Profile

11.13. Netazepide (YF476): Trio Medicines

11.13.1. Product Description

11.13.2. Safety and Efficacy

11.13.3. Product Profile

12. Gastroenteropancreatic Neuroendocrine Tumors: 7 Major Market Analysis

12.1. Key Findings

12.2. Market Size of Gastroenteropancreatic Neuroendocrine Tumors in 7MM

12.3. Market Outlook

12.4. The United States Market Size

12.4.1. Total Market Size of Gastroenteropancreatic Neuroendocrine Tumors in the United States

12.4.2. Market Size of Gastroenteropancreatic Neuroendocrine Tumors by Therapies in the United States……

12.5. Market Size of Gastroenteropancreatic Neuroendocrine Tumors in EU-5

12.5.1. Market Size of Gastroenteropancreatic Neuroendocrine Tumors by Therapies in Germany

12.5.2. Market Size of Gastroenteropancreatic Neuroendocrine Tumors by Therapies in France

12.5.3. Market Size of Gastroenteropancreatic Neuroendocrine Tumors by Therapies in Italy

12.5.4. Market Size of Gastroenteropancreatic Neuroendocrine Tumors by Therapies in Spain

12.5.5. Market Size of Gastroenteropancreatic Neuroendocrine Tumors by Therapies in the United Kingdom

12.6. Japan Market Size

12.6.1. Total Market Size of Gastroenteropancreatic Neuroendocrine Tumors in Japan

12.6.2. Market Size of Gastroenteropancreatic Neuroendocrine Tumors by Therapies in Japan

13. KOL View

14. SWOT

15. Unmet Needs

16. Market Access

17. Appendix

17.1. Bibliography

17.2. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

List of Table

Table 1: Summary of Gastroenteropancreatic neuroendocrine tumors, Market, Epidemiology, and Key Events

Table 2: Definitions for GEP-NETs According to the WHO Classifications

Table 3: Definition of Tumor Grading for GEP-NETs According to the WHO 2010 classification            

Table 4: Incidence of Gastroenteropancreatic Neuroendocrine Tumors in the 7MM (2019–2032)

Table 5: Incidence of Gastroenteropancreatic Neuroendocrine Tumors in the United States (2019–2032)

Table 6: Grade-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in the United States (2019–2032)

Table 7: Tumor site-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in the United States

Table 8: Stage-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in the United States

Table 9: Symptom-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in the United States (2019–2032)

Table 10: Incidence of Gastroenteropancreatic Neuroendocrine Tumors in EU5 (2019–2032)

Table 11: Grade-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Germany (2019–2032)

Table 12: Tumor site-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Germany (2019–2032)

Table 13: Stage-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Germany (2019–2032)

Table 14: Symptom-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Germany

Table 15: Grade-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in France (2019–2032)

Table 16: Tumor site-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in France (2019–2032)

Table 17: Stage-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in France (2019–2032)

Table 18: Symptom-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in France (2019–2032)

Table 19: Grade-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Italy (2019–2032)

Table 20: Tumor site-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Italy (2019–2032)

Table 21: Stage-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Italy (2019–2032)

Table 22: Symptom-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Italy (2019–2032)

Table 23: Grade-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Spain (2019–2032)

Table 24: Tumor site-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Spain (2019–2032)

Table 25: Stage-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Spain (2019–2032)

Table 26: Symptom-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Spain (2019–2032)

Table 27: Grade-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in the United Kingdom (2019–2032)

Table 28: Tumor site-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in the United Kingdom

Table 29: Stage-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in the United Kingdom (2019–2032)

Table 30: Symptom-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in the United Kingdom (2019–2032)

Table 31: Incidence of Gastroenteropancreatic Neuroendocrine Tumors in Japan (2019–2032)

Table 32: Grade-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in  Japan  (2019–2032)

Table 33: Tumor site-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Japan (2019–2032)

Table 34: Stage-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Japan (2019–2032)

Table 35: Symptom-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Japan (2019–2032)

Table 36: Key Competitors: Emerging Therapies

Table 37: 177Lu-edotreotide PRRT, Clinical Trial Description, 2022

Table 38: CAM2029, Clinical Trial Description, 2022

Table 39: Surufatinib, Clinical Trial Description, 2022

Table 40: Opdivo, Clinical Trial Description, 2022

Table 41: Lenvatinib, Clinical Trial Description, 2022

Table 42: PEN-221, Clinical Trial Description, 2022

Table 43: Cabozantinib, Clinical Trial Description, 2022

Table 44: Key Cross of Other Assets in Development

Table 45: Key Cross of Other Assets in Development

Table 46: Keytruda, Clinical Trial Description, 2022

Table 47: Entrectinib, Clinical Trial Description, 2022

Table 48: SOM 230, Clinical Trial Description, 2022

Table 49:  Abemaciclib, Clinical Trial Description, 2022

Table 50: Belzutifan, Clinical Trial Description, 2022

Table 51: Atezolizumab+Tivozanib, Clinical Trial Description, 2022

Table 52: Alectinib, Clinical Trial Description, 2022

Table 53: AlphaMedix, Clinical Trial Description, 2022

Table 54: Ramucirumab, Clinical Trial Description, 2022

Table 55: Lurbinectedin, Clinical Trial Description, 2022

Table 56: Regorafenib, Clinical Trial Description, 2022

Table 57: Seven Major Market Size of Gastroenteropancreatic Neuroendocrine Tumors in USD Million (2019–2032)

Table 58: Market Size of Gastroenteropancreatic Neuroendocrine Tumors in the United States in USD Million (2019–2032)

Table 59: The US Market Size of Gastroenteropancreatic Neuroendocrine Tumors by Therapies in USD Million (2019–2032)

Table 60: EU5 Market Size of Gastroenteropancreatic Neuroendocrine Tumors in USD Million (2019–2032)

Table 61: Market Size of Gastroenteropancreatic Neuroendocrine Tumors by Therapies in Germany in USD Million (2019–2032)

Table 62: Market Size of Gastroenteropancreatic Neuroendocrine Tumors  by Therapies in France in USD Million (2019–2032)

Table 63: Market Size of Gastroenteropancreatic Neuroendocrine Tumors by Therapies in Italy in USD Million (2019–2032)

Table 64: Market Size of Gastroenteropancreatic Neuroendocrine Tumors by Therapies in Spain in USD Million (2019–2032)

Table 65: Market Size of Gastroenteropancreatic Neuroendocrine Tumors by Therapies in the United Kingdom in USD Million (2019–2032)

Table 66: Market Size of Gastroenteropancreatic Neuroendocrine Tumors in Japan in USD Million (2019–2032)

Table 67: Japan Market Size of Gastroenteropancreatic Neuroendocrine Tumors by Therapies in USD Million (2019–2032)

Table 68: Programs to help with the cost of medicine to treat GEP-NET

Table 69: Lutetium, National Institute for Health and Care Excellence (NICE) comments

List of Figures

Figure 1: Causes of Neuroendocrine Tumors

Figure 2: Symptoms of Gastroenteropancreatic Neuroendocrine tumor

Figure 3: Treatment of Gastroenteropancreatic Neuroendocrine tumor

Figure 4: Treatment Algorithm for Gastroenteropancreatic Neuroendocrine Tumor

Figure 5: Total Incident Population of Gastroenteropancreatic Neuroendocrine Tumors in 7MM (2019–2032)

Figure 6: Incidence of Gastroenteropancreatic Neuroendocrine Tumors in the United States (2019–2032)

Figure 7: Grade-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in the United States (2019–2032)

Figure 8: Tumor site-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in the United States (2019–2032)

Figure 9: Stage-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in the United States (2019–2032)

Figure 10: Symptom-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in the United States (2019–2032)

Figure 11: Total Incident Population of Gastroenteropancreatic Neuroendocrine Tumors in EU5 (2019–2032)

Figure 12: Grade-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Germany (2019–2032)

Figure 13: Tumor site-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Germany (2019–2032)

Figure 14: Stage-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Germany (2019–2032)

Figure 15: Symptom-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Germany (2019–2032)

Figure 16: Grade-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in France (2019–2032)

Figure 17: Tumor site-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in France (2019–2032)

Figure 18: Stage-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in France (2019–2032)

Figure 19: Symptom-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in France (2019–2032)

Figure 20: Grade-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Italy (2019–2032)

Figure 21: Tumor site-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Italy  (2019–2032)

Figure 22: Stage-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Italy (2019–2032)

Figure 23: Symptom-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Italy (2019–2032)

Figure 24: Grade-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Spain (2019–2032)

Figure 25: Tumor site-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Spain (2019–2032)

Figure 26: Stage-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Spain

Figure 27: Symptom-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Spain (2019–2032)

Figure 28: Grade-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in the United Kingdom (2019–2032)

Figure 29: Tumor site-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in the United Kingdom (2019–2032)

Figure 30: Stage-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in the United Kingdom (2019–2032)

Figure 31: Symptom-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in the United Kingdom (2019–2032)

Figure 32: Incidence of Gastroenteropancreatic Neuroendocrine Tumors in Japan (2019–2032)

Figure 33: Grade-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Japan (2019–2032)

Figure 34: Tumor site-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Japan (2019–2032)

Figure 35: Stage-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Japan (2019–2032)

Figure 36: Symptom-specific cases of Gastroenteropancreatic Neuroendocrine Tumors in Japan  (2019–2032)

Figure 37: Seven Major Market Size of Gastroenteropancreatic Neuroendocrine Tumors in USD Million (2019–2032)

Figure 38: Market Size of Gastroenteropancreatic Neuroendocrine Tumors in the United States in USD Million (2019–2032)

Figure 39: Market Size of Gastroenteropancreatic Neuroendocrine Tumors in the United States by Therapies (2019–2032)

Figure 40: EU5 Market Size of Gastroenteropancreatic Neuroendocrine Tumors in USD Million (2019–2032)

Figure 41: Market Size of Gastroenteropancreatic Neuroendocrine Tumors in Germany by Therapies (2019–2032)

Figure 42: Market Size of Gastroenteropancreatic Neuroendocrine Tumors in France by Therapies (2019–2032)

Figure 43: Market Size of Gastroenteropancreatic Neuroendocrine Tumors in Italy by Therapies (2019–2032)

Figure 44: Market Size of Gastroenteropancreatic Neuroendocrine Tumors in Spain by Therapies (2019–2032)

Figure 45: Market Size of Gastroenteropancreatic Neuroendocrine Tumors in the United Kingdom by Therapies (2019–2032)

Figure 46: Market Size of Gastroenteropancreatic Neuroendocrine Tumors in Japan in USD Million (2019–2032)

Figure 47: Market Size of Gastroenteropancreatic Neuroendocrine Tumors in Japan by Therapies (2019–2032)

Novartis

Ipsen Biopharmaceuticals

Pfizer

ITM Isotopen Technologien Muenchen

Camurus AB

Hutchison Medipharma Limited

Bristol-Myers Squibb

Eisai Limite

Experior S.L.

Tarveda Therapeutics

Roche Pharma A

Exelixis

Merck Sharp & Dohme Corp

Recordati Inc

Eli Lilly and Company

Genentech, Inc.

Aveo Oncology Pharmaceuticals

Radiomedix

Orano Med

PharmaMar

Bayer

Trio Medicines

Forward to Friend

Need A Quote